MX2009006081A - Compuestos y composiciones como inhibidores de cinasa de proteina. - Google Patents

Compuestos y composiciones como inhibidores de cinasa de proteina.

Info

Publication number
MX2009006081A
MX2009006081A MX2009006081A MX2009006081A MX2009006081A MX 2009006081 A MX2009006081 A MX 2009006081A MX 2009006081 A MX2009006081 A MX 2009006081A MX 2009006081 A MX2009006081 A MX 2009006081A MX 2009006081 A MX2009006081 A MX 2009006081A
Authority
MX
Mexico
Prior art keywords
compounds
protein kinase
compositions
kinase inhibitors
kinase
Prior art date
Application number
MX2009006081A
Other languages
English (en)
Inventor
Tao Jiang
Thomas H Marsilje
Tetsuo Uno
Pierre-Yves Michellys
Wei Pei
Wenshuo Lu
Bei Chen
Yunho Jin
Original Assignee
Irmc Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39370882&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009006081(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irmc Llc filed Critical Irmc Llc
Publication of MX2009006081A publication Critical patent/MX2009006081A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

La invención proporciona novedosos derivados de pirimidina y piridina de la fórmula (I) y composiciones farmacéuticas de los mismos, y método para utilizar estos compuestos. Por ejemplo, los derivados de pirimidina y piridina de la invención se pueden utilizar para tratar, aminorar o prevenir una condición que responda a la inhibición de la actividad de la cinasa de linfoma anaplásico (ALK) la cinasa de adhesión focal (FAK), la cinasa de proteína asociada con cadena Zeta 70 (ZAP-70), el factor de crecimiento tipo insulina (IGF-1R), o una combinación de los mismos.
MX2009006081A 2006-12-08 2007-11-20 Compuestos y composiciones como inhibidores de cinasa de proteina. MX2009006081A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86929906P 2006-12-08 2006-12-08
US96644907P 2007-08-28 2007-08-28
PCT/US2007/085304 WO2008073687A2 (en) 2006-12-08 2007-11-20 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2009006081A true MX2009006081A (es) 2009-06-17

Family

ID=39370882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006081A MX2009006081A (es) 2006-12-08 2007-11-20 Compuestos y composiciones como inhibidores de cinasa de proteina.

Country Status (30)

Country Link
EP (1) EP2091918B1 (es)
JP (3) JP5208123B2 (es)
KR (1) KR101149295B1 (es)
CN (2) CN103641833A (es)
AU (3) AU2007333394C1 (es)
BR (1) BRPI0720264B1 (es)
CA (1) CA2671744C (es)
CO (1) CO6231028A2 (es)
CR (1) CR10832A (es)
CY (1) CY2015043I1 (es)
DK (1) DK2091918T3 (es)
EA (1) EA017405B9 (es)
EC (1) ECSP099500A (es)
FR (1) FR15C0058I2 (es)
GT (1) GT200900147A (es)
HU (1) HUS1500049I1 (es)
IL (1) IL198936A0 (es)
LT (1) LTC2091918I2 (es)
MA (1) MA30923B1 (es)
ME (1) ME00811B (es)
MX (1) MX2009006081A (es)
NL (1) NL300763I1 (es)
NO (3) NO338069B1 (es)
PL (1) PL2091918T3 (es)
PT (1) PT2091918E (es)
SM (1) SMP200900058B (es)
SV (1) SV2009003290A (es)
TN (1) TN2009000225A1 (es)
WO (1) WO2008073687A2 (es)
ZA (1) ZA200903601B (es)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045663A2 (en) * 2006-10-06 2008-04-17 Kalypsys, Inc. Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents
WO2008051547A1 (en) 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
KR101149295B1 (ko) * 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
WO2008079719A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
DK2134689T3 (da) 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US8440681B2 (en) 2007-08-28 2013-05-14 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
WO2009032694A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
ES2569734T3 (es) 2007-09-21 2016-05-12 Array Biopharma, Inc. Derivados de piridin-2-il-tiourea y de piridin-2-il-amina como intermedios para la preparación de piridin-2-il-amino-1,2,4-tiadiazoles activadores de la glucocinasa
US20100317663A1 (en) * 2008-02-19 2010-12-16 Jerry Leroy Adams Anilinopyridines as inhibitors of fak
CA2720946C (en) * 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2303861B1 (en) 2008-06-17 2014-04-23 AstraZeneca AB Pyridine compounds
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
MX2010014568A (es) * 2008-06-25 2011-03-29 Irm Llc Derivados de pirmidina como inhibidores de cinasa.
DK2361248T3 (en) 2008-06-27 2019-01-14 Celgene Car Llc Heteroberl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010025850A1 (de) * 2008-09-03 2010-03-11 Bayer Cropscience Ag Heterozyklisch substituierte anilinopyrimidine als fungizide
WO2010114894A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
ES2659725T3 (es) * 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
WO2010128659A1 (ja) 2009-05-08 2010-11-11 アステラス製薬株式会社 ジアミノへテロ環カルボキサミド化合物
EP2435422B1 (en) 2009-05-27 2014-12-17 AbbVie Inc. Pyrimidine inhibitors of kinase activity
EP3205647B1 (en) 2009-08-17 2020-05-13 Memorial Sloan-Kettering Cancer Center 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders
WO2011034907A2 (en) 2009-09-16 2011-03-24 Avila Therapeutics, Inc. Protein kinase conjugates and inhibitors
EP2512246B1 (en) 2009-12-17 2015-09-30 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
SG181803A1 (en) 2009-12-17 2012-07-30 Merck Sharp & Dohme Aminopyrimidines as syk inhibitors
MX2012007684A (es) 2009-12-30 2012-10-05 Avila Therapeutics Inc Modificacion covalente ligando dirigida de proteina.
JP2013522215A (ja) 2010-03-09 2013-06-13 オーエスアイ・ファーマシューティカルズ，エルエルシー 組合わせ抗癌療法
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
EP3144298A1 (en) 2010-08-10 2017-03-22 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
MX2013004894A (es) 2010-11-01 2013-10-17 Celgene Avilomics Res Inc Compuestos heterociclicos y usos de los mismos.
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
PT3124483T (pt) 2010-11-10 2019-10-02 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2
MY177742A (en) * 2010-12-17 2020-09-23 Novartis Ag Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
BR112013019643B1 (pt) * 2011-02-02 2022-04-19 Novartis Ag Uso de inibidores de álcali
GB201104267D0 (en) * 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
MX2013013090A (es) 2011-05-10 2013-12-16 Merck Sharp & Dohme Aminopirimidinas como inhibidores de tirosina cinaza del bazo.
EP2707357B1 (en) 2011-05-10 2017-01-18 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
EP2802568A1 (en) 2012-01-13 2014-11-19 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents.
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
MX356179B (es) 2012-03-15 2018-05-17 Celgene Avilomics Res Inc Sales de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
JP6317319B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の固体形態
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2014071832A1 (en) * 2012-11-06 2014-05-15 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
RU2015121424A (ru) * 2012-11-07 2016-12-27 Новартис Аг Комбинированная терапия
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
CA2914310A1 (en) * 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
CA2917735C (en) * 2013-07-11 2017-04-18 Betta Pharmaceuticals Co., Ltd Protein tyrosine kinase modulators and methods of use
JP6564771B2 (ja) 2013-07-11 2019-08-21 エイシア バイオサイエンシーズ インコーポレイテッド キナーゼ阻害剤としてのピリミジン誘導体
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
BR112016004358A8 (pt) * 2013-08-28 2020-02-11 Novartis Ag combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
RU2016129953A (ru) * 2013-12-23 2018-01-30 Новартис Аг Фармацевтические комбинации
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
PT3116909T (pt) 2014-03-14 2020-01-30 Novartis Ag Moléculas de anticorpos para lag-3 e suas utilizações
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CN106456640B (zh) 2014-05-29 2021-05-14 诺华股份有限公司 色瑞替尼制剂
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN103992262B (zh) * 2014-06-12 2015-11-11 苏州明锐医药科技有限公司 塞瑞替尼及其中间体的制备方法
CN106459007B (zh) * 2014-06-17 2020-02-28 韩国化学研究院 嘧啶-2，4-二胺衍生物及包含其作为有效成分的抗癌用药学组合物
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
EP3191097B1 (en) 2014-09-13 2019-10-23 Novartis AG Combination therapies
EP3202765B1 (en) * 2014-09-29 2020-03-25 Hainan Xuanzhu Pharma Co., Ltd. Polycyclic anaplastic lymphoma kinase inhibitor
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX2017004810A (es) 2014-10-14 2017-10-16 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
EP3206717B1 (en) 2014-10-17 2020-11-25 Novartis AG Combination of ceritinib with an egfr inhibitor
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
WO2016098042A1 (en) 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
CN105777617B (zh) * 2014-12-26 2018-11-06 上海医药工业研究院 色瑞替尼的合成中间体及其制备方法
CN105777616B (zh) * 2014-12-26 2018-12-07 上海医药工业研究院 色瑞替尼的合成中间体及其制备方法
EP3778605A3 (en) 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
US9296721B1 (en) * 2015-02-13 2016-03-29 Yong Xu Method for preparing ALK inhibitor ceritinib
CA2976981A1 (en) 2015-03-04 2016-09-09 Novartis Ag Chemical process for preparing pyrimidine derivatives and intermediates thereof
AR103894A1 (es) 2015-03-10 2017-06-14 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del estimulador del gen interferón
CN106146387A (zh) * 2015-03-30 2016-11-23 湖北生物医药产业技术研究院有限公司 Alk抑制剂的制备方法
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
CZ2015613A3 (cs) 2015-09-09 2017-03-22 Zentiva, K.S. Způsob přípravy Ceritinibu
CN111848586A (zh) * 2015-09-25 2020-10-30 迪哲（江苏）医药有限公司 用于抑制jak的化合物和方法
CN107949388B (zh) 2015-10-09 2021-10-26 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
CN106565593B (zh) * 2015-10-10 2019-03-01 常州市勇毅生物药业有限公司 一种色瑞替尼中间体的制备方法
JP2019500892A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｔｉｍ−３に特異的に結合する抗体及びその使用
CN106699743B (zh) * 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
PT3380465T (pt) * 2015-11-26 2020-10-23 Novartis Ag Derivados de diamino piridina
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017153932A1 (en) 2016-03-10 2017-09-14 Novartis Ag Strn-alk fusion as a therapeutic target in gastric cancer
WO2017175111A1 (en) 2016-04-04 2017-10-12 Novartis Ag Strn-alk fusion as a therapeutic target in colorectal cancer
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
KR101937529B1 (ko) * 2016-07-26 2019-01-14 한국화학연구원 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
RU2769132C2 (ru) 2017-01-10 2022-03-28 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
EP3585486A1 (en) 2017-02-27 2020-01-01 Novartis AG Dosing schedule for a combination of ceritinib and an anti-pd-1 antibody molecule
CA3059072A1 (en) 2017-04-07 2018-10-11 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
CN110092759A (zh) * 2018-01-31 2019-08-06 陆柯潮 作为抗肿瘤药物的5-氯-2,4-嘧啶衍生物
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
AU2019294835A1 (en) * 2018-06-29 2020-12-17 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
CN109593065A (zh) * 2018-12-03 2019-04-09 重庆医科大学 一类hdac/alk双靶点抑制剂及其制备方法与应用
TWI769470B (zh) * 2019-06-25 2022-07-01 大陸商蘇州亞盛藥業有限公司 用於治療疾病的fak抑制劑和btk抑制劑的組合
CA3145864A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN112538072B (zh) * 2019-09-21 2024-02-06 齐鲁制药有限公司 氨基嘧啶类egfr抑制剂
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
WO2021098883A1 (zh) * 2019-11-21 2021-05-27 浙江同源康医药股份有限公司 用作egfr激酶抑制剂的化合物及其应用
KR102472103B1 (ko) * 2019-12-03 2022-11-29 삼진제약주식회사 국소 부착 키나아제 저해제로서 신규한 아다만탄 유도체
KR102572704B1 (ko) * 2019-12-16 2023-08-30 한국화학연구원 신규한 피리미딘 유도체 및 이의 용도
EP4129996A4 (en) * 2020-03-23 2023-07-12 Qilu Pharmaceutical Co., Ltd. NEW EGFR AMINOPYRIMIDINE INHIBITOR
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
WO2023106881A1 (ko) * 2021-12-09 2023-06-15 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약학 조성물
WO2023109751A1 (zh) * 2021-12-13 2023-06-22 希格生科（深圳）有限公司 嘧啶或吡啶类衍生物及其医药用途
CN115368366A (zh) * 2022-08-02 2022-11-22 江苏省中医药研究院 嘧啶并吡唑类化合物及其应用
CN115448906B (zh) * 2022-09-26 2024-04-02 深圳大学 一种2-苯胺基嘧啶类衍生物及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236161T1 (de) * 1995-11-01 2003-04-15 Novartis Pharma Gmbh Purinderivate und verfahren zu ihrer herstellung
WO2000012485A1 (en) * 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US20030125344A1 (en) * 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
AR035792A1 (es) * 2001-03-23 2004-07-14 Bayer Corp Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
WO2003059913A1 (en) * 2002-01-10 2003-07-24 Bayer Healthcare Ag Roh-kinase inhibitors
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0319227D0 (en) * 2003-08-15 2003-09-17 Novartis Ag Organic compounds
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
CN1798734A (zh) * 2003-04-04 2006-07-05 Irm责任有限公司 作为蛋白激酶抑制剂的新化合物和组合物
EP1656378A4 (en) * 2003-08-15 2011-05-11 Irm Llc COMPOUNDS AND COMPOSITIONS INHIBITING TYROSINE KINASE RECEPTOR ACTIVITY
NZ585188A (en) * 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CA2590110C (en) * 2004-12-30 2014-06-03 Exelixis, Inc. Kinase modulators and method of use
WO2008051547A1 (en) * 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
KR101149295B1 (ko) * 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물

Also Published As

Publication number Publication date
CY2015043I2 (el) 2016-04-13
JP5208123B2 (ja) 2013-06-12
NO20160333A1 (no) 2016-02-29
MA30923B1 (fr) 2009-11-02
KR20090087127A (ko) 2009-08-14
AU2010210019B2 (en) 2012-08-02
AU2010210018A1 (en) 2010-09-02
CA2671744C (en) 2012-08-28
BRPI0720264A2 (pt) 2011-05-10
NO338069B1 (no) 2016-07-25
HUS1500049I1 (hu) 2017-10-30
GT200900147A (es) 2010-01-27
NO2016014I1 (es) 2016-08-10
DK2091918T3 (en) 2014-12-01
JP5513558B2 (ja) 2014-06-04
NL300763I2 (es) 2016-02-09
EA017405B1 (ru) 2012-12-28
AU2007333394C1 (en) 2011-08-18
AU2007333394A1 (en) 2008-06-19
CN103641816A (zh) 2014-03-19
PL2091918T3 (pl) 2015-02-27
AU2007333394B2 (en) 2011-02-03
JP2010512329A (ja) 2010-04-22
NO2016014I2 (no) 2016-08-10
JP2013144683A (ja) 2013-07-25
AU2010210019A1 (en) 2010-09-02
ZA200903601B (en) 2011-01-26
CO6231028A2 (es) 2010-12-20
BRPI0720264B1 (pt) 2022-03-03
AU2010210019C1 (en) 2013-02-14
NO20092472L (no) 2009-09-02
EA017405B9 (ru) 2014-05-30
CA2671744A1 (en) 2008-06-19
CY2015043I1 (el) 2016-04-13
LTC2091918I2 (lt) 2017-04-10
ME00811B (me) 2012-03-20
WO2008073687A3 (en) 2008-07-31
EP2091918A2 (en) 2009-08-26
WO2008073687A2 (en) 2008-06-19
JP2012229240A (ja) 2012-11-22
FR15C0058I2 (fr) 2016-03-11
FR15C0058I1 (es) 2015-10-02
EP2091918B1 (en) 2014-08-27
SMAP200900058A (it) 2010-01-19
IL198936A0 (en) 2010-02-17
PT2091918E (pt) 2014-11-24
SV2009003290A (es) 2010-08-17
NL300763I1 (es) 2016-02-09
KR101149295B1 (ko) 2012-07-05
CN103641833A (zh) 2014-03-19
SMP200900058B (it) 2010-11-12
CR10832A (es) 2009-07-14
EA200970557A1 (ru) 2009-12-30
AU2010210018B2 (en) 2012-02-02
ECSP099500A (es) 2009-08-28
TN2009000225A1 (en) 2010-10-18

Similar Documents

Publication Publication Date Title
JO2980B1 (en) Compounds and structures used as inhibitors of protein kinase
EA017405B9 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
MX2010002336A (es) Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
WO2010002655A3 (en) Pyrimidine derivatives as kinase inhibitors
MX2010010968A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
WO2009126514A8 (en) Compounds and compositions as kinase inhibitors
WO2009158431A3 (en) Pyrimidine derivatives as kinase inhibitors
WO2008049123A8 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2007079164A3 (en) Protein kinase inhibitors
MX2010005950A (es) 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa.
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
MY148634A (en) Pyridazinone derivatives
GEP20105074B (en) Pyrimidinyl aryl urea derivatives being fgf inhibitors
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
IL179883A0 (en) 4,6-disubstituted pyrimidine derivatives and pharmaceutical compositions containing the same
MX2008001538A (es) Aril piridinas y metodos para su uso.
WO2008042282A3 (en) Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011012632A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
UA96265C2 (ru) Композиция и способ ингибирования jak пути передачи сигнала
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
TN2010000602A1 (en) Pyrimidine derivatives as kinase inhibitors

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration
GD Licence granted
GD Licence granted
PD Change of proprietorship

Owner name: NOVARTIS AG.*